Mario Abinun

Mario Abinun

Auto-generated profile, based on publicly available information

Mario Abinun

Immunity & Inflammation Theme, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2008 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
MGMatteo M. Guerrini
Matteo M. Guerrini
CSCristina Sobacchi
Cristina Sobacchi
BCBarbara Cassani
Barbara Cassani
MAMario Abinun
Mario Abinun
SKSara Sebnem Kilic
Sara Sebnem Kilic
AFAnnalisa Frattini
Annalisa Frattini

24 August 2018 in Science
Verified
Journal Article
Closed access
PDF file
DCDelphine Cuchet-Lourenço
Delphine Cuchet-Lourenço
DEDavide Eletto
Davide Eletto
CWChangxin Wu
Changxin Wu
VPVincent Plagnol
Vincent Plagnol
OPOlivier Papapietro
Olivier Papapietro
SNSergey Nejentsev
Sergey Nejentsev
Humans as models of human disease: Mice are a convenient model for exploring the functions of cellular signaling pathways. Occasionally, however, an “experiment of nature” highlights the perils of overreliance on mice. RIPK1 is a well studied protein kinase that regulates cell death. Mice deficient in RIPK1 die soon after birth because of the protein's widespread role in multiple tissues and organs. Cuchet-Lourenço et al. studied patients with inherited immunodeficiency of unknown cause (see the Perspective by Pasparakis and Kelliher). They identified inactivating mutations in the RIPK1 gene in four individuals. Unlike what has been seen in mice, the deleterious effects of RIPK1 loss in humans were confined to the immune system, a finding with potential therapeutic implications. Science , this issue p. 810 ; see also p. 756

23 October 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
TCTim D Cheetham
Tim D Cheetham
MCMichael Cole
Michael Cole
MAMario Abinun
Mario Abinun
AAAmit Allahabadia
Amit Allahabadia
TBTim Barratt
Tim Barratt
SPSimon H S Pearce
Simon H S Pearce
Context: Remission rates in young people with Graves hyperthyroidism are less than 25% after 2 years of thionamide antithyroid drug (ATD). Objective: We explored whether rituximab (RTX), a B-lymphocyte–depleting agent, would increase remission rates when administered with a short course of ATD. Methods: This was an open-label, multicenter, single-arm, phase 2 trial in young people (ages, 12-20 years) with Graves hyperthyroidism. An A’Hern design was used to distinguish an encouraging remission rate (40%) from an unacceptable rate (20%). Participants presenting with Graves hyperthyroidism received 500 mg RTX and 12 months of ATD titrated according to thyroid function. ATDs were stopped after 12 months and primary outcome assessed at 24 months. Participants had relapsed at 24 months if thyrotropin was suppressed and free 3,5,3′-triiodothyronine was raised; they had received ATD between months 12 and 24; or they had thyroid surgery/radioiodine. Results: A total of 27 participants were recruited and completed the trial with no serious side effects linked to treatment. Daily carbimazole dose at 12 months was less than 5 mg in 21 of 27 participants. Thirteen of 27 participants were in remission at 24 months (48%, 90% one-sided CI, 35%-100%); this exceeded the critical value (9) for the A’Hern design and provided evidence of a promising remission rate. B-lymphocyte count at 28 weeks, expressed as a percentage of baseline, was related to likelihood of remission. Conclusion: Adjuvant RTX, administered with a 12-month course of ATD, may increase the likelihood of remission in young people with Graves hyperthyroidism. A randomized trial of adjuvant RTX in young people with Graves hyperthyroidism is warranted.

19 March 2020 in Blood
Verified
Journal Article
Open access
PDF file
SLSu Han Lum
Su Han Lum
CAClaire Anderson
Claire Anderson
PMPeter McNaughton
Peter McNaughton
KEKarin Regine Engelhardt
Karin Regine Engelhardt
BMBrigid MacKenzie
Brigid MacKenzie
MSMary Slatter
Mary Slatter
MHC class II deficiency is a rare, but life-threatening, primary combined immunodeficiency. Hematopoietic cell transplantation (HCT) remains the only curative treatment for this condition, but transplant survival in the previously published result was poor. We analyzed the outcome of 25 patients with MHC class II deficiency undergoing first HCT at Great North Children's Hospital between 1995 and 2018. Median age at diagnosis was 6.5 months (birth to 7.5 years). Median age at transplant was 21.4 months (0.1-7.8 years). Donors were matched family donors (MFDs; n = 6), unrelated donors (UDs; n = 12), and haploidentical donors (HIDs; n = 7). Peripheral blood stem cells were the stem cell source in 68% of patients. Conditioning was treosulfanbased in 84% of patients; 84% received alemtuzumab (n = 14) or anti-thymocyte globulin (n = 8) as serotherapy. With a 2.9-year median follow-up, OS improved from 33% (46-68%) for HCT before 2008 (n = 6) to 94% (66-99%) for HCT after 2008 (n = 19; P = .003). For HCT after 2008, OS according to donor was 100% for MFDs and UDs and 85% for HIDs (P = .40). None had grade III-IV acute or chronic graft-versus-host disease. Latest median donor myeloid and lymphocyte chimerism were 100% (range, 0-100) and 100% (range, 64-100), respectively. Latest CD4+ T-lymphocyte number was significantly lower in transplant survivors (n = 14) compared with posttransplant disease controls (P = .01). All survivors were off immunoglobulin replacement and had protective vaccine responses to tetanus and Haemophilus influenzae. None had any significant infection or autoimmunity. Changing transplant strategy in Great North Children's Hospital has significantly improved outcomes for MHC class II deficiency.


2 December 2016
Verified
Book Chapter
Closed access
PDF file
UWUwe Wintergerst
Uwe Wintergerst
TKTaco W. Kuijpers
Taco W. Kuijpers
SRSergio D. Rosenzweig
Sergio D. Rosenzweig
SHSteven M. Holland
Steven M. Holland
MAMario Abinun
Mario Abinun
NRNima Rezaei
Nima Rezaei